Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of SkQ1 Ophthalmic Solution in Dry Eye Syndrome
NCT04206020Phase 3Completed
- Sponsor
- Mitotech
- Start
- Dec 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye syndrome (DED) comparing SkQ1 with Placebo (2 arms). Primary endpoints: Change from Baseline to Visit 5 of Ocular Discomfort at Day 57 and Change from Baseline to Visit 5 of conjunctival fluorescein staining at Day 57. Started Dec 2019; status: completed.
02
Drugs
SkQ1
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT04206020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04206020.